{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:24:42Z","timestamp":1781299482677,"version":"3.54.1"},"reference-count":147,"publisher":"Impact Journals, LLC","issue":"37","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,11,24]]},"DOI":"10.18632\/oncotarget.3999","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T21:54:23Z","timestamp":1443563663000},"page":"39521-39537","source":"Crossref","is-referenced-by-count":27,"title":["Novel agents for advanced pancreatic cancer"],"prefix":"10.18632","volume":"6","author":[{"given":"Akintunde","family":"Akinleye","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, New York Medical College, Valhalla, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitanya","family":"Iragavarapu","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, New York Medical College, Valhalla, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Furqan","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Iowa, Iowa City, Iowa, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shundong","family":"Cang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Henan Province People's Hospital, Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,6,3]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00006676-200410000-00002","article-title":"Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells","volume":"29","author":"Wilson","year":"2004","journal-title":"Pancreas"},{"key":"2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Jemal","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"3","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/S0140-6736(12)61688-2","article-title":"Global burden of cancer: opportunities for prevention","volume":"380","author":"Jemal","year":"2012","journal-title":"Lancet"},{"key":"4","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1097\/MPA.0b013e318291fbc5","article-title":"Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008","volume":"42","author":"Koeberle","year":"2013","journal-title":"Pancreas"},{"key":"5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/SLA.0b013e31821fd334","article-title":"Pancreatic cancer surgery in the new millennium: better prediction of outcome","volume":"254","author":"Werner","year":"2011","journal-title":"Ann Surg"},{"key":"6","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","volume":"350","author":"Buchler","year":"2004","journal-title":"N Engl J Med"},{"key":"7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial","volume":"297","author":"Riess","year":"2007","journal-title":"JAMA"},{"key":"8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1172\/JCI30082","article-title":"The pancreatic stellate cell: a star on the rise in pancreatic diseases","volume":"117","author":"Pandol","year":"2007","journal-title":"J Clin Invest"},{"key":"9","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.cgh.2009.07.039","article-title":"Desmoplasia of pancreatic ductal adenocarcinoma","volume":"7","author":"Gukovskaya","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/00000478-200405000-00008","article-title":"The pancreatic duct and its arteriovenous relationship: an underutilized aid in the diagnosis and distinction of pancreatic adenocarcinoma from pancreatic intraepithelial neoplasia. A study of 126 pancreatectomy specimens","volume":"28","author":"Green","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"11","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2010.1275","article-title":"Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial","volume":"304","author":"Buchler","year":"2010","journal-title":"JAMA"},{"key":"12","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/sj.bjc.6605256","article-title":"A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer","volume":"101","author":"Kanemitsu","year":"2009","journal-title":"Br J Cancer"},{"key":"13","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMra0901557","article-title":"Pancreatic cancer","volume":"362","author":"Hidalgo","year":"2010","journal-title":"N Engl J Med"},{"key":"14","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Ducreux","year":"2011","journal-title":"N Engl J Med"},{"key":"15","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Renschler","year":"2013","journal-title":"N Engl J Med"},{"key":"16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1756-8722-7-18","article-title":"Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies","volume":"7","author":"Mesa","year":"2014","journal-title":"Journal of Hematology & Oncology"},{"key":"17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1756-8722-6-27","article-title":"MEK and the inhibitors: from bench to bedside","volume":"6","author":"Liu","year":"2013","journal-title":"J Hematol Oncol"},{"key":"18","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-08-2954","article-title":"andradiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase\/extracellular signal-regulated kinase 1\/2 kinase","volume":"15","author":"Citrin","year":"2009","journal-title":"Clin Cancer Res"},{"key":"19","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1158\/1078-0432.CCR-08-3021","article-title":"Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer","volume":"15","author":"Hidalgo","year":"2009","journal-title":"Clin Cancer Res"},{"key":"20","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1007\/s10637-011-9687-4","article-title":"A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy","volume":"30","author":"Tebbutt","year":"2012","journal-title":"Invest New Drugs"},{"key":"21","first-page":"407","article-title":"Kras as a key oncogene and therapeutic target in pancreatic cancer","volume":"4","author":"Pasca di Magliano","year":"2013","journal-title":"Front Physiol"},{"key":"22","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.18632\/oncotarget.1890","article-title":"CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFR","volume":"5","author":"Zhao","year":"2014","journal-title":"Oncotarget"},{"key":"23","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1200\/JCO.2009.25.4433","article-title":"Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study","volume":"28","author":"Perrone","year":"2010","journal-title":"J Clin Oncol"},{"key":"24","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1200\/JCO.2009.24.2446","article-title":"Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer","volume":"27","author":"Neoptolemos","year":"2009","journal-title":"J Clin Oncol"},{"key":"25","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1200\/JCO.2008.20.9007","article-title":"Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group","volume":"27","author":"Benson","year":"2009","journal-title":"J Clin Oncol"},{"key":"26","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1200\/JCO.2006.07.0201","article-title":"Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer","volume":"24","author":"O'Reilly","year":"2006","journal-title":"J Clin Oncol"},{"key":"27","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bjc.6603301","article-title":"A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer","volume":"95","author":"Georgoulias","year":"2006","journal-title":"Br J Cancer"},{"key":"28","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/annonc\/mdi309","article-title":"A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer","volume":"16","author":"Kindler","year":"2005","journal-title":"Ann Oncol"},{"key":"29","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.2002.11.149","article-title":"Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297","volume":"20","author":"Benson","year":"2002","journal-title":"J Clin Oncol"},{"key":"30","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2009.25.7550","article-title":"Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205","volume":"28","author":"Blanke","year":"2010","journal-title":"J Clin Oncol"},{"key":"31","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1200\/JCO.2010.28.1386","article-title":"Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)","volume":"28","author":"Goldberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv1027","article-title":"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Ganitumab or Placebo in Combination With Gemcitabine as First-Line Therapy for Metastatic Adenocarcinoma of the Pancreas: the GAMMA Trial","volume":"26","author":"Carrato","year":"2015","journal-title":"Annals of Oncology"},{"key":"33","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/annonc\/mds135","article-title":"BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer","volume":"23","author":"Raoul","year":"2012","journal-title":"Ann Oncol"},{"key":"34","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(11)70004-3","article-title":"Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study","volume":"12","author":"Van Cutsem","year":"2011","journal-title":"Lancet Oncol"},{"key":"35","first-page":"4035","article-title":"Prospective randomized phase II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: A study of the CESAR Central European Society for Anticancer Drug Research-EWIV","volume":"31","author":"Bergmann","year":"2013","journal-title":"ASCO Meeting Abstracts"},{"key":"36","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/j.ejca.2013.04.002","article-title":"Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer","volume":"49","author":"Philip","year":"2013","journal-title":"Eur J Cancer"},{"key":"37","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2004.10.112","article-title":"Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer","volume":"22","author":"Von Hoff","year":"2004","journal-title":"J Clin Oncol"},{"key":"38","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.2008.18.9514","article-title":"Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer","volume":"27","author":"Fuchs","year":"2009","journal-title":"J Clin Oncol"},{"key":"39","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.ejca.2014.04.024","article-title":"A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas","volume":"50","author":"Le","year":"2014","journal-title":"Eur J Cancer"},{"key":"40","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Parulekar","year":"2007","journal-title":"J Clin Oncol"},{"key":"41","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/annonc\/mdn015","article-title":"A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes","volume":"19","author":"Fujiwara","year":"2008","journal-title":"Ann Oncol"},{"key":"42","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/91000","article-title":"Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity","volume":"7","author":"Zhou","year":"2001","journal-title":"Nat Med"},{"key":"43","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1074-7613(00)80211-3","article-title":"FADD\/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2","volume":"12","author":"Walczak","year":"2000","journal-title":"Immunity"},{"key":"44","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0092-8674(00)81590-1","article-title":"Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis","volume":"94","author":"Yuan","year":"1998","journal-title":"Cell"},{"key":"45","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.gassur.2006.08.007","article-title":"Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viabilityand growth","volume":"10","author":"Vickers","year":"2006","journal-title":"J Gastrointest Surg"},{"key":"46","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1158\/1535-7163.MCT-07-0299","article-title":"TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth","volume":"6","author":"Buchsbaum","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/cbr.2009.0673","article-title":"Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)","volume":"25","author":"Saleh","year":"2010","journal-title":"Cancer Biother Radiopharm"},{"key":"48","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/cam4.137","article-title":"Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer","volume":"2","author":"Saleh","year":"2013","journal-title":"Cancer Med"},{"key":"49","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1128\/JVI.66.1.374-385.1992","article-title":"Enhancement of transforming potential of human insulinlike growth factor 1 receptor by N-terminal truncation and fusion to avian sarcoma virus UR2 gag sequence","volume":"66","author":"Wang","year":"1992","journal-title":"Journal of virology"},{"key":"50","doi-asserted-by":"crossref","first-page":"6835","DOI":"10.1128\/JVI.67.11.6835-6840.1993","article-title":"Distinctive effects of the carboxyl-terminal sequence of the insulin-like growth factor I receptor on its signaling functions","volume":"67","author":"Wang","year":"1993","journal-title":"Journal of virology"},{"key":"51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1128\/JVI.67.1.9-18.1993","article-title":"Modulating effects of the extracellular sequence of the human insulinlike growth factor I receptor on its transforming and tumorigenic potential","volume":"67","author":"Wang","year":"1993","journal-title":"Journal of virology"},{"key":"52","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF02257980","article-title":"Oncogenes, Protein Tyrosine Kinases, and Signal Transduction","volume":"1","author":"Wang","year":"1994","journal-title":"Journal of biomedical science"},{"key":"53","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/carcin\/bgn026","article-title":"FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells","volume":"29","author":"Hochwald","year":"2008","journal-title":"Carcinogenesis"},{"key":"54","first-page":"2007","article-title":"Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles","volume":"55","author":"Korc","year":"1995","journal-title":"Cancer Res"},{"key":"55","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/ijc.24186","article-title":"Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor","volume":"124","author":"Goetsch","year":"2009","journal-title":"Int J Cancer"},{"key":"56","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.ejca.2007.03.009","article-title":"Functional responses andanti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin\/IGF-1 hybrid receptors","volume":"43","author":"Goetsch","year":"2007","journal-title":"Eur J Cancer"},{"key":"57","first-page":"361","article-title":"Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer","volume":"12","author":"Cascinu","year":"2010","journal-title":"Curr Opin Mol Ther"},{"key":"58","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ijc.20543","article-title":"A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts","volume":"113","author":"Corvaia","year":"2005","journal-title":"Int J Cancer"},{"key":"59","doi-asserted-by":"crossref","first-page":"6304","DOI":"10.1158\/1078-0432.CCR-10-3336","article-title":"A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors","volume":"17","author":"Baselga","year":"2011","journal-title":"Clin Cancer Res"},{"key":"60","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.4026","article-title":"Randomized phase II study of gemcitabine (G) plus anti-IGF-1R antibody MK-0646, G plus erlotinib (E) plus MK-0646 and G plus E for advanced pancreatic cancer","volume":"29","author":"Javle","year":"2011","journal-title":"J Clin Oncol"},{"key":"61","doi-asserted-by":"crossref","first-page":"618","DOI":"10.4161\/cbt.9.8.11264","article-title":"Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types","volume":"9","author":"Gliniak","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"62","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0304-3835(00)00660-1","article-title":"Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer","volume":"163","author":"Buchler","year":"2001","journal-title":"Cancer Lett"},{"key":"63","article-title":"A phase Ib study to evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (PC)","volume":"27","author":"Stephenson","year":"2009","journal-title":"J Clin Oncol"},{"key":"64","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/annonc\/mds142","article-title":"A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer","volume":"23","author":"Fuchs","year":"2012","journal-title":"Ann Oncol"},{"key":"65","doi-asserted-by":"crossref","first-page":"5549s","DOI":"10.1158\/1078-0432.CCR-07-1109","article-title":"IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor","volume":"13","author":"Ludwig","year":"2007","journal-title":"Clin Cancer Res"},{"key":"66","first-page":"8912","article-title":"A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth","volume":"63","author":"Ludwig","year":"2003","journal-title":"Cancer Res"},{"key":"67","first-page":"A269","article-title":"A phase I, first in man study of weekly IMC-A12, a fully human insulin-like growth factor receptor IgG1 monoclonal antibody in patients with advanced solid tumors","author":"Whiting","year":"2007","journal-title":"ASCO"},{"key":"68","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1002\/cncr.28744","article-title":"Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)","volume":"120","author":"Blanke","year":"2014","journal-title":"Cancer"},{"key":"69","article-title":"Characterization of a re-combinant, fully human monoclonal antibody directed against the human insulin-like growth factor-1 receptor","author":"Rebers","year":"2006","journal-title":"18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Poster #214"},{"key":"70","article-title":"IGF-1R (RO4858696) Roche Clinical Study Report-Protocol BO19373","author":"F. Hoffmann-La Roche Ltd","year":"2009","journal-title":"Research Report 1027082"},{"key":"71","first-page":"867","article-title":"A humanized anti-IGF-1R monoclonal antibody (R1507) and\/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells","volume":"27","author":"Funakoshi","year":"2012","journal-title":"Oncol Rep"},{"key":"72","article-title":"Effect of R1507, an anti-IGF-1R monocolonal antibody, on sensitization of pancreatic cancer cell lines to mTOR inhibition","author":"Pineda","year":"2010","journal-title":"Gastrointestinal Cancers Symposium"},{"key":"73","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1158\/1078-0432.CCR-09-3220","article-title":"A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors","volume":"16","author":"Gore","year":"2010","journal-title":"Clin Cancer Res"},{"key":"74","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00280-011-1759-9","article-title":"Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial","volume":"69","author":"Morris","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"75","first-page":"4320","article-title":"Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma","volume":"61","author":"Hruban","year":"2001","journal-title":"Cancer Res"},{"key":"76","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canlet.2008.08.034","article-title":"Prostate stem cell antigen: a prospective therapeutic and diagnostic target","volume":"277","author":"Kast","year":"2009","journal-title":"Cancer Lett"},{"key":"77","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1073\/pnas.051624698","article-title":"Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts","volume":"98","author":"Jakobovits","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"78","doi-asserted-by":"crossref","first-page":"9495","DOI":"10.1158\/0008-5472.CAN-05-2086","article-title":"Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell deathand inhibits tumor growthvia a Fc-independent mechanism","volume":"65","author":"Reiter","year":"2005","journal-title":"Cancer Res"},{"key":"79","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1093\/annonc\/mds078","article-title":"A phase I\/IIA study of AGS-PSCA for castration-resistant prostate cancer","volume":"23","author":"Carducci","year":"2012","journal-title":"Ann Oncol"},{"key":"80","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/annonc\/mdt066","article-title":"Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer","volume":"24","author":"Hidalgo","year":"2013","journal-title":"Ann Oncol"},{"key":"81","article-title":"Phase Ib of anticancer stem cell antibody OMP-59R5 (anti-Notch2\/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC)","volume":"32","author":"Bendell","year":"2014","journal-title":"J Clin Oncol"},{"key":"82","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10637-014-0083-8","article-title":"A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma","volume":"32","author":"Messersmith","year":"2014","journal-title":"Invest New Drugs"},{"key":"83","first-page":"iv210","article-title":"Final results of a phase 1b of OMP-59R5 (anti-notch2\/3\/stem cell antibody) in combination with nab-paclitaxel and gemcitabine (Nab-P + Gem) in patients with untreated metastatic pancreatic cancer","volume":"25","author":"Smith","year":"2014","journal-title":"Annals of Oncology"},{"key":"84","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1002\/cncr.27592","article-title":"Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial","volume":"118","author":"Goldenberg","year":"2012","journal-title":"Cancer"},{"key":"85","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrc1251","article-title":"Mucins in cancer: protection and control of the cell surface","volume":"4","author":"Swanson","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"86","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1158\/1078-0432.CCR-07-1488","article-title":"PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma","volume":"13","author":"Hruban","year":"2007","journal-title":"Clin Cancer Res"},{"key":"87","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1158\/1055-9965.EPI-10-0667","article-title":"Detection of early-stage pancreatic adenocarcinoma","volume":"19","author":"Goldenberg","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"88","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1756-8722-5-68","article-title":"Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy","volume":"5","author":"Batra","year":"2012","journal-title":"Journal of Hematology & Oncology"},{"key":"89","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/sj.onc.1206291","article-title":"MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion","volume":"22","author":"Gendler","year":"2003","journal-title":"Oncogene"},{"key":"90","doi-asserted-by":"crossref","first-page":"20607","DOI":"10.1074\/jbc.M310538200","article-title":"The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase\/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts","volume":"279","author":"Kufe","year":"2004","journal-title":"J Biol Chem"},{"key":"91","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2005.01.008","article-title":"Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response","volume":"7","author":"Kufe","year":"2005","journal-title":"Cancer Cell"},{"key":"92","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ijc.2910570213","article-title":"Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin","volume":"57","author":"Cardillo","year":"1994","journal-title":"Int J Cancer"},{"key":"93","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/(SICI)1097-0215(19970516)71:4<660::AID-IJC24>3.0.CO;2-E","article-title":"Radioimmunotherapy of experimental pancreatic cancer with 131I-labeled monoclonal antibody PAM4","volume":"71","author":"Blumenthal","year":"1997","journal-title":"Int J Cancer"},{"key":"94","first-page":"3186","article-title":"Therapeutic advantage of (90)yttrium- versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer","volume":"7","author":"Gold","year":"2001","journal-title":"Clin Cancer Res"},{"key":"95","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/ijc.1613","article-title":"Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer","volume":"97","author":"Gold","year":"2002","journal-title":"Int J Cancer"},{"key":"96","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/ijc.20004","article-title":"Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft","volume":"109","author":"Cardillo","year":"2004","journal-title":"Int J Cancer"},{"key":"97","first-page":"3929S","article-title":"Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer","volume":"9","author":"Cardillo","year":"2003","journal-title":"Clin Cancer Res"},{"key":"98","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1158\/1078-0432.CCR-10-2579","article-title":"Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial","volume":"17","author":"Goldenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"99","first-page":"5s","article-title":"Feasibility and results of a randomized phase lb study of fractionated 90Y-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies","volume":"32","author":"Lowery","year":"2014","journal-title":"J Clin Oncol"},{"key":"100","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Hauschild","year":"2012","journal-title":"N Engl J Med"},{"key":"101","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1016\/j.bmcl.2009.08.049","article-title":"GDC-0449-a potent inhibitor of the hedgehog pathway","volume":"19","author":"Wong","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"102","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1158\/1078-0432.CCR-06-1736","article-title":"The hedgehog signaling pathway in cancer","volume":"12","author":"de Sauvage","year":"2006","journal-title":"Clin Cancer Res"},{"key":"103","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/aps.2012.24","article-title":"Hedgehog signaling pathway mediates invasion and metastasis of hepatocellular carcinoma via ERK pathway","volume":"33","author":"Wei","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"104","doi-asserted-by":"crossref","first-page":"854","DOI":"10.18632\/oncotarget.586","article-title":"Regulation of DNA damage following termination of Hedgehog (HH) survival signaling at the level of the GLI genes in human colon cancer","volume":"3","author":"Houghton","year":"2012","journal-title":"Oncotarget"},{"key":"105","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.canlet.2012.11.039","article-title":"Progress from clinical trials and emerging non-conventional therapies for the treatment of Medulloblastomas","volume":"330","author":"Kamnasaran","year":"2013","journal-title":"Cancer Lett"},{"key":"106","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1158\/0008-5472.CAN-12-1248","article-title":"Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K\/AKT pathway","volume":"72","author":"Majumder","year":"2012","journal-title":"Cancer Res"},{"key":"107","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/B978-0-12-394622-5.00020-1","article-title":"Activation of Hedgehog pathway in gastrointestinal cancers","volume":"88","author":"Xie","year":"2012","journal-title":"Vitam Horm"},{"key":"108","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.4161\/cc.22134","article-title":"Developmental pathways in colon cancer: crosstalk between WNT, BMP, Hedgehog and Notch","volume":"11","author":"Sigounas","year":"2012","journal-title":"Cell Cycle"},{"key":"109","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nature02009","article-title":"Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis","volume":"425","author":"Hebrok","year":"2003","journal-title":"Nature"},{"key":"110","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.bcp.2004.01.002","article-title":"Regulation of Hedgehog signaling: a complex story","volume":"67","author":"Robbins","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"111","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1056\/NEJMcibr0905857","article-title":"The hedgehog pathway and pancreatic cancer","volume":"361","author":"Maitra","year":"2009","journal-title":"N Engl J Med"},{"key":"112","doi-asserted-by":"crossref","first-page":"e27306","DOI":"10.1371\/journal.pone.0027306","article-title":"Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms","volume":"6","author":"Shankar","year":"2011","journal-title":"PLoS One"},{"key":"113","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.tips.2009.03.007","article-title":"Mechanisms of Hedgehog pathway activation in cancer and implications for therapy","volume":"30","author":"de Sauvage","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"114","article-title":"Final analysis of a phase IB\/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago phase II consortium study","volume":"31","author":"Nattam","year":"2013","journal-title":"J Clin Oncol"},{"key":"115","article-title":"A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA)","volume":"32","author":"Ramanathan","year":"2014","journal-title":"J Clin Oncol"},{"key":"116","doi-asserted-by":"crossref","first-page":"e7258","DOI":"10.1371\/journal.pone.0007258","article-title":"Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT","volume":"4","author":"Hermine","year":"2009","journal-title":"PLoS One"},{"key":"117","doi-asserted-by":"crossref","first-page":"e9430","DOI":"10.1371\/journal.pone.0009430","article-title":"Masitinib combined with standard gemcitabine chemotherapy:andstudies in human pancreatic tumour cell lines and ectopic mouse model","volume":"5","author":"Dubreuil","year":"2010","journal-title":"PLoS One"},{"key":"118","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.ejca.2009.05.010","article-title":"Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and\/or metastatic solid cancers","volume":"45","author":"Armand","year":"2009","journal-title":"Eur J Cancer"},{"key":"119","first-page":"15s","article-title":"Oral tyrosine kinase inhibitor masitinib in combination with gemcitabine in patients with advanced pancreatic cancer: A multicenter phase II study","volume":"27","author":"Deplanque","year":"2009","journal-title":"J Clin Oncol"},{"key":"120","article-title":"Masitinib in nonresectable pancreatic cancer: Results of a phase III randomized placebo-controlled trial","volume":"31","author":"Hebbar","year":"2013","journal-title":"J Clin Oncol"},{"key":"121","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-06-1150","article-title":"Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1\/2 inhibitor","volume":"13","author":"Wallace","year":"2007","journal-title":"Clin Cancer Res"},{"key":"122","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.2007.14.4956","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1\/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers","volume":"26","author":"Eckhardt","year":"2008","journal-title":"J Clin Oncol"},{"key":"123","article-title":"Dual MEK\/EGFR inhibition for advanced, chemotherapy-refractory pancreatic cancer: A multicenter phase II trial of selumetinib (AZD6244; ARRY-142886) plus erlotinib","volume":"31","author":"Bekaii-Saab","year":"2013","journal-title":"J Clin Oncol"},{"key":"124","doi-asserted-by":"crossref","first-page":"6365","DOI":"10.1038\/onc.2008.250","article-title":"Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530","volume":"27","author":"Evans","year":"2008","journal-title":"Oncogene"},{"key":"125","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s10637-010-9611-3","article-title":"A phase I\/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer","volume":"30","author":"Seymour","year":"2012","journal-title":"Invest New Drugs"},{"key":"126","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2141.2010.08127.x","article-title":"Blockade of the MEK\/ERK signalling cascade by AS703026, a novel selective MEK1\/2 inhibitor, induces pleiotropic anti-myeloma activityand","volume":"149","author":"Tai","year":"2010","journal-title":"Br J Haematol"},{"key":"127","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1158\/0008-5472.CAN-10-3058","article-title":"MEK1\/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy","volume":"71","author":"Choi","year":"2011","journal-title":"Cancer Res"},{"key":"128","article-title":"Pimasertib plus gemcitabine in metastatic pancreatic adenocarcinoma: Results of a safety run-in part of a phase II trial","volume":"31","author":"Hidalgo","year":"2013","journal-title":"J Clin Oncol"},{"key":"129","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1158\/0008-5472.CAN-09-0679","article-title":"RDEA119\/BAY 869766: a potent, selective, allosteric inhibitor of MEK1\/2 for the treatment of cancer","volume":"69","author":"Quart","year":"2009","journal-title":"Cancer Res"},{"key":"130","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/1471-2407-10-515","article-title":"Antitumour activity of a potent MEK inhibitor RDEA119\/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts","volume":"10","author":"Hedley","year":"2010","journal-title":"BMC Cancer"},{"key":"131","first-page":"5s","article-title":"Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1\/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer","volume":"32","author":"Heinemann","year":"2014","journal-title":"J Clin Oncol"},{"key":"132","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1158\/0008-5472.CAN-10-2933","article-title":"Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase","volume":"71","author":"Verma","year":"2011","journal-title":"Cancer Res"},{"key":"133","article-title":"Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-\u0394) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with gemcitabine in patients with advanced cancer","volume":"31","author":"Nadal","year":"2013","journal-title":"J Clin Oncol"},{"key":"134","doi-asserted-by":"crossref","first-page":"A121","DOI":"10.1158\/1535-7163.TARG-09-A121","article-title":"Novel PARP inhibitors with potent antitumor activity as single-agent and combination therapies","volume":"8","author":"Feng","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"135","article-title":"First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors","volume":"31","author":"Gonzalez","year":"2013","journal-title":"J Clin Oncol"},{"key":"136","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","article-title":"ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models","volume":"13","author":"Shi","year":"2007","journal-title":"Clin Cancer Res"},{"key":"137","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.e13542","article-title":"The use of PARP inhibitors as single agents and as chemosensitizers in sporadic pancreatic cancer","volume":"29","author":"De Soto","year":"2011","journal-title":"J Clin Oncol"},{"key":"138","first-page":"5s","article-title":"Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC)","volume":"32","author":"Segal","year":"2014","journal-title":"J Clin Oncol"},{"key":"139","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1200\/JCO.1999.17.11.3631","article-title":"Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development","volume":"17","author":"Von Hoff","year":"1999","journal-title":"J Clin Oncol"},{"key":"140","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1038\/sj.onc.1202602","article-title":"A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice","volume":"18","author":"Kloog","year":"1999","journal-title":"Oncogene"},{"key":"141","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1007\/s10637-012-9818-6","article-title":"Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer","volume":"30","author":"Hidalgo","year":"2012","journal-title":"Invest New Drugs"},{"key":"142","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2217\/fon.10.71","article-title":"Salirasib in the treatment of pancreatic cancer","volume":"6","author":"Tsimberidou","year":"2010","journal-title":"Future Oncol"},{"key":"143","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.18632\/oncotarget.724","article-title":"Superior efficacy of co-treatment with dual PI3K\/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer","volume":"3","author":"Bhalla","year":"2012","journal-title":"Oncotarget"},{"key":"144","doi-asserted-by":"crossref","first-page":"183","DOI":"10.18632\/oncoscience.28","article-title":"Sirtainties in pancreatic cancer?","volume":"1","author":"Rooman","year":"2014","journal-title":"Oncoscience"},{"key":"145","doi-asserted-by":"crossref","first-page":"9150","DOI":"10.18632\/oncotarget.2363","article-title":"Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer","volume":"5","author":"Hong","year":"2014","journal-title":"Oncotarget"},{"key":"146","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-015-0122-8","article-title":"Novel ALK inhibitors in clinical use and development","volume":"8","author":"Liu","year":"2015","journal-title":"Journal of Hematology & Oncology"},{"key":"147","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-015-0141-5","article-title":"Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future","volume":"8","author":"Sun","year":"2015","journal-title":"Journal of Hematology & Oncology"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.3999","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T18:39:59Z","timestamp":1692038399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.3999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,3]]},"references-count":147,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2015,11,24]]}},"alternative-id":["3999","26369833"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.3999","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,3]]}}}